MML Investors Services LLC Buys 28,130 Shares of AbbVie Inc. $ABBV

MML Investors Services LLC increased its stake in shares of AbbVie Inc. (NYSE:ABBV) by 4.5% during the 4th quarter, Holdings Channel reports. The fund owned 659,523 shares of the company’s stock after acquiring an additional 28,130 shares during the period. MML Investors Services LLC’s holdings in AbbVie were worth $150,694,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Chelsea Counsel Co. bought a new position in AbbVie during the third quarter worth $26,000. Litman Gregory Wealth Management LLC bought a new position in AbbVie during the fourth quarter worth $28,000. Westend Capital Management LLC bought a new position in shares of AbbVie in the fourth quarter valued at $29,000. IFC & Insurance Marketing Inc. bought a new position in shares of AbbVie in the fourth quarter valued at $31,000. Finally, Texas Capital Bancshares Inc TX bought a new position in shares of AbbVie in the third quarter valued at $31,000. 70.23% of the stock is owned by institutional investors.

AbbVie Price Performance

ABBV opened at $227.54 on Monday. The company’s 50-day moving average is $211.05 and its 200 day moving average is $219.00. AbbVie Inc. has a fifty-two week low of $181.73 and a fifty-two week high of $244.81. The firm has a market capitalization of $402.02 billion, a P/E ratio of 112.09, a PEG ratio of 0.70 and a beta of 0.32.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The company had revenue of $15 billion for the quarter, compared to analyst estimates of $14.72 billion. During the same period last year, the firm earned $2.46 earnings per share. The firm’s revenue was up 12.4% on a year-over-year basis. On average, equities research analysts expect that AbbVie Inc. will post 14.3 earnings per share for the current year.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie said nine-year CLL14 data showed venetoclax plus obinutuzumab delivered durable progression-free survival in previously untreated chronic lymphocytic leukemia, strengthening the case for the drug’s long-term commercial value. AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results
• Positive Sentiment: Investors are also focused on AbbVie’s broader pipeline and franchise strength, with commentary pointing to Skyrizi and Rinvoq continuing to drive revenue growth, which supports the company’s outlook beyond legacy Humira. Will Skyrizi & Rinvoq Continue to Drive AbbVie’s Topline Through 2026?
• Neutral Sentiment: Several market commentaries described AbbVie as a defensive, high-quality compounder, but noted the shares may not be cheap at current levels, which suggests valuation may temper upside even with strong fundamentals. AbbVie: A Defensive Compounder Worth Holding, But Not A Bargain Buy
• Negative Sentiment: One article highlighted regulatory risk around AbbVie’s fast-acting neurotoxin TrenibotE after an FDA complete response letter, which could delay a potential growth driver if development setbacks persist. FDA Issues Complete Response Letter for AbbVie’s Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. William Blair reaffirmed an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a research note on Monday, June 8th. Bank of America raised shares of AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 price objective on the stock in a research note on Thursday, April 30th. Canaccord Genuity Group raised their price objective on shares of AbbVie from $262.00 to $265.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $240.00 price objective on shares of AbbVie in a research note on Thursday, April 30th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $253.43.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.